The UK's National Institute for Health and Care Excellence (NICE) has for the second time recommended against making Janssen's antidepressant spray Spravato (esketamine) available on England's National Health Service.
Janssen to Address NICE's Concerns Following Another English Funding No For Spravato
UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
![Target](https://insights.citeline.com/resizer/v2/7WDOQMMX2RKCBBQZC7BBI6VS6I.jpg?smart=true&auth=09ae8c48f0cd1758718e9bc1ea62c9a8fb729950b67fbc4a87e77354d4b220b5&width=700&height=394)
More from Health Technology Assessment
More from Market Access
Company dossiers submitted for EU-level joint clinical assessments under the Health Technology Assessment Regulation will be made public. This could conflict with other strategic business decisions and should be planned for in advance, experts say.
President Trump’s 10% tariff on active pharmaceutical ingredients and finished dosage forms could push some generic drug makers to exit therapeutic categories if they cannot absorb the new costs, which could lead to shortages.
Several first-term Trump veterans are returning to leadership roles at the US Centers for Medicare and Medicaid Services ahead of the expected confirmation of Mehmet Oz to lead the agency.